Literature DB >> 11811782

Hematopoietic stem cell transplantation: current status of old issues.

N Kapoor1.   

Abstract

Since 1968 hematopoietic stem cell transplantation (HSCT) has progressed from an experimental to standard therapeutic procedure. There are many obstacles to the successful outcome of HSCT procedures. Some of these obstacles are lack of healthy histocompatible donors, graft versus host disease, graft rejection and infections. Many advances have been made to overcome these obstacles with significant success. However, these issues and associated problems continue to persist at different levels as the field evolves with expanding indications for HSCT, use of alternative sources for hematopoietic stem cells and alternative transplant procedures. Newer interventions have allowed us to overcome some of these obstacles.

Entities:  

Mesh:

Year:  2001        PMID: 11811782     DOI: 10.1023/a:1013197825053

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  22 in total

Review 1.  Treatment of Epstein-Barr virus-associated posttransplant lymphoproliferative disorders.

Authors:  T G Gross
Journal:  J Pediatr Hematol Oncol       Date:  2001-01       Impact factor: 1.289

2.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.

Authors:  J Kurtzberg; M Laughlin; M L Graham; C Smith; J F Olson; E C Halperin; G Ciocci; C Carrier; C E Stevens; P Rubinstein
Journal:  N Engl J Med       Date:  1996-07-18       Impact factor: 91.245

Review 3.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

4.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.

Authors:  M J Laughlin; J Barker; B Bambach; O N Koc; D A Rizzieri; J E Wagner; S L Gerson; H M Lazarus; M Cairo; C E Stevens; P Rubinstein; J Kurtzberg
Journal:  N Engl J Med       Date:  2001-06-14       Impact factor: 91.245

5.  Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children.

Authors:  F Legrand; D Berrebi; N Houhou; F Freymuth; A Faye; M Duval; J F Mougenot; M Peuchmaur; E Vilmer
Journal:  Bone Marrow Transplant       Date:  2001-03       Impact factor: 5.483

6.  Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation.

Authors:  J A Hoffman; A J Shah; L A Ross; N Kapoor
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

7.  Large-scale DNA-based typing of HLA-A and HLA-B at low resolution is highly accurate specific and reliable.

Authors:  C K Hurley; M Maiers; J Ng; D Wagage; J Hegland; J Baisch; R Endres; M Fernandez-Vina; U Heine; S Hsu; M Kamoun; Y Mitsuishi; D Monos; H Noreen; L Perlee; S Rodriguez-Marino; A Smith; P Stastny; M Trucco; S Y Yang; N Yu; R Holsten; R J Hartzman; M Setterholm
Journal:  Tissue Antigens       Date:  2000-04

8.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  R E Champlin; N Schmitz; M M Horowitz; B Chapuis; R Chopra; J J Cornelissen; R P Gale; J M Goldman; F R Loberiza; B Hertenstein; J P Klein; E Montserrat; M J Zhang; O Ringdén; S C Tomany; P A Rowlings; M E Van Hoef; A Gratwohl
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

Review 9.  Cytokine dysregulation and acute graft-versus-host disease.

Authors:  J H Antin; J L Ferrara
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

10.  Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F).

Authors:  E Holler; H J Kolb; J Mittermüller; M Kaul; G Ledderose; T Duell; B Seeber; M Schleuning; R Hintermeier-Knabe; B Ertl
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.